SharpView Ophthalmology Limited

12/09/2024

🌟 What an incredible experience at !

This event is a truly special opportunity to meet friends and colleagues from around the world, exchanging ideas and insights that inspire progress in ophthalmology.

Thank you to everyone who took the time to visit our booth and attend the EyeMax Mono presentations. Your feedback was truly inspiring.

Watch the highlights from this year’s congress and keep an eye out for what’s next!

21/06/2024

🔬 Advancing therapies for neovascular and diabetic macular edema (DME) is crucial due to their impact on quality of life. In a Modern Retina Viewpoints discussion, Dr. Nathan Steinle and experts highlighted the latest treatments and strategies. Key insights included the effectiveness of anti-VEGF agents, benefits of combination therapy, and the potential of sustained-release drug delivery systems.

Patient education, real-world evidence, and advances in retinal imaging were also emphasized as vital for improving outcomes. Ongoing research is essential to continue these advancements.

Find out more 👇

A panel of esteemed retina specialists recently delved into innovative therapies for neovascular age-related macular degeneration and diabetic macular edema, focusing on personalized treatment, telemedicine, and the ongoing quest for advancements.

19/06/2024

«Through the years of experience that I have gathered with the lens, I have seen how patients continue to be happy with the results, including patients whose macular degeneration has progressed significantly. They continue to be happy because we have done everything we could to offer them better vision»

Watch the full interview with Dr Jairo Hoyos Chacón of the Hoyos Ophthalmology Institute, in Sabadell (Spain), as he shares his firsthand experience using EyeMax Mono - click to watch the video now

EyeMax Mono User ExperienceROUND OF INTERVIEWSOn this occasion we have the honor of sharing the testimony of Dr. Jairo Hoyos Chacón, from Hoyos Ophthalmology...

17/06/2024

🔬 Harvard scientists have created a detailed cell atlas of the human eye, identifying nearly 160 cell types and their gene expressions. This breakthrough, led by neurobiologist Joshua Sanes, could pave the way for targeted gene therapies for glaucoma and macular degeneration, which cause blindness in millions. The findings, published in PNAS, offer a blueprint for designing effective therapeutic strategies. Discover more about this pioneering research in this article from Medical Xpress - Medical and Health News

Glaucoma and macular degeneration cause blindness in millions of people every year. Hundreds of genes have been implicated for increasing susceptibility to the diseases, and such genes are often starting points for therapies that prevent or reverse blindness. But it's not always clear where, when, a...

14/06/2024

Fascinating study by Annah P. Baykal, MD, and colleagues! They examined how Leonardo da Vinci’s sfumato technique in paintings is perceived by individuals with different types of vision loss. While overall perception did not vary significantly by vision type, men with AMD and POAG reported lower contentment scores compared to women. This suggests 𝗻𝘂𝗮𝗻𝗰𝗲𝗱 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲 𝗼𝗳 𝘃𝗶𝘀𝗶𝗼𝗻 𝗹𝗼𝘀𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗴𝗲𝗻𝗱𝗲𝗿𝘀. Learn more about this intriguing intersection of art and ophthalmology. Find out more in this article from Healio

https://www.healio.com/news/ophthalmology/20230908/subtle-differences-in-disease-burden-of-vision-loss-may-exist-between-sexes

MARCO ISLAND, Fla. — A study tested the hypothesis that Leonardo da Vinci’s paintings utilizing the sfumato technique may be perceived differently by people with central vision loss vs. peripheral vision loss.

03/05/2024

🔍 A study published in The Lancet suggests that avacincaptad pegol, a complement component 5 inhibitor, could slow geographic atrophy lesion growth. Over 12 months, patients receiving avacincaptad pegol experienced significantly slower progression compared to those on sham treatment. Though adverse events were reported, none were severe. However, questions remain about long-term effectiveness and safety, emphasizing the need for ongoing vigilance.
👉 Learn more in this article from Healio

The complement component 5 inhibitor avacincaptad pegol may have potential as a treatment to reduce geographic atrophy lesion growth and slow progression of disease, according to a study published in The Lancet.“The results of GATHER2 showed that monthly C5 inhibition with avacincaptad pegol 2...

30/04/2024

🔸 𝘛𝘩𝘦 𝘴𝘶𝘳𝘨𝘪𝘤𝘢𝘭 𝘪𝘯𝘴𝘦𝘳𝘵𝘪𝘰𝘯 𝘵𝘦𝘤𝘩𝘯𝘪𝘲𝘶𝘦 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘌𝘺𝘦𝘔𝘢𝘹 𝘔𝘰𝘯𝘰 𝘪𝘴 𝘴𝘪𝘮𝘪𝘭𝘢𝘳 𝘵𝘰 𝘵𝘩𝘢𝘵 𝘰𝘧 𝘢𝘯𝘺 𝘮𝘰𝘯𝘰𝘧𝘰𝘤𝘢𝘭 𝘭𝘦𝘯𝘴. 𝘏𝘰𝘸𝘦𝘷𝘦𝘳, 𝘵𝘩𝘦 𝘌𝘺𝘦𝘔𝘢𝘹 𝘔𝘰𝘯𝘰 𝘥𝘪𝘴𝘵𝘪𝘯𝘨𝘶𝘪𝘴𝘩𝘦𝘴 𝘪𝘵𝘴𝘦𝘭𝘧 𝘧𝘳𝘰𝘮 𝘵𝘳𝘢𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘮𝘰𝘯𝘰𝘧𝘰𝘤𝘢𝘭 𝘭𝘦𝘯𝘴𝘦𝘴 𝘢𝘴 𝘪𝘵𝘴 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘰𝘱𝘵𝘪𝘤 𝘱𝘭𝘢𝘵𝘦 𝘣𝘰𝘢𝘴𝘵𝘴 𝘢 𝘸𝘢𝘷𝘦𝘧𝘳𝘰𝘯𝘵-𝘮𝘰𝘥𝘪𝘧𝘪𝘦𝘥 𝘱𝘳𝘰𝘧𝘪𝘭𝘦, 𝘦𝘯𝘢𝘣𝘭𝘪𝘯𝘨 𝘤𝘰𝘳𝘳𝘦𝘤𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘵𝘳𝘢𝘯𝘴𝘷𝘦𝘳𝘴𝘦 𝘴𝘱𝘩𝘦𝘳𝘪𝘤𝘢𝘭 𝘢𝘣𝘦𝘳𝘳𝘢𝘵𝘪𝘰𝘯. 𝘛𝘩𝘪𝘴 𝘶𝘯𝘪𝘲𝘶𝘦 𝘧𝘦𝘢𝘵𝘶𝘳𝘦 𝘦𝘹𝘱𝘢𝘯𝘥𝘴 𝘵𝘩𝘦 𝘧𝘰𝘤𝘶𝘴 𝘢𝘳𝘦𝘢 𝘰𝘯 𝘵𝘩𝘦 𝘳𝘦𝘵𝘪𝘯𝘢 𝘶𝘱 𝘵𝘰 𝟣𝟢° 𝘧𝘳𝘰𝘮 𝘵𝘩𝘦 𝘮𝘢𝘤𝘶𝘭𝘢.

Watch the full interview with Dr Patrizia Busatto, Trieste, Italy as she shares her first-hand experience using EyeMax Mono.

Dr Patrizia Busatto - 41st Congress of ESCRS, Vienna 2023

26/04/2024

AMD treatment is advancing, with multiple therapies available for wet AMD and research focusing on dry AMD. Dr. Kaustabh Ghosh from UCLA discussed the need for interventions targeting early stages, emphasizing the importance of understanding vascular degeneration mechanisms. His multidisciplinary approach aims to identify molecular targets to preserve vision. Collaborative efforts between basic scientists and clinicians hold promise for revolutionizing AMD.
Find out more in this article from Modern Retina by David Hutton

Few treatment options available for early stages of disease.

17/04/2024

🔸 𝘐 𝘳𝘦𝘤𝘰𝘮𝘮𝘦𝘯𝘥 𝘵𝘩𝘦 𝘌𝘺𝘦𝘔𝘢𝘹 𝘔𝘰𝘯𝘰 𝘭𝘦𝘯𝘴 𝘵𝘰 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘢𝘵𝘳𝘰𝘱𝘩𝘪𝘤 𝘢𝘯𝘥 𝘴𝘵𝘢𝘣𝘭𝘦 𝘮𝘢𝘤𝘶𝘭𝘢𝘳 𝘥𝘦𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘸𝘩𝘪𝘤𝘩 𝘪𝘴 𝘯𝘰𝘵 𝘵𝘰𝘰 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥. 𝘚𝘰𝘮𝘦𝘵𝘪𝘮𝘦𝘴, 𝘢𝘥𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘰𝘱𝘵𝘪𝘤𝘢𝘭 𝘤𝘰𝘳𝘳𝘦𝘤𝘵𝘪𝘰𝘯 𝘤𝘢𝘯 𝘩𝘦𝘭𝘱 𝘶𝘴 𝘢𝘤𝘩𝘪𝘦𝘷𝘦 𝘢𝘯 𝘦𝘷𝘦𝘯 𝘣𝘦𝘵𝘵𝘦𝘳 𝘷𝘪𝘴𝘶𝘢𝘭 𝘧𝘶𝘯𝘤𝘵𝘪𝘰𝘯, 𝘦𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘭𝘺 𝘧𝘰𝘳 𝘯𝘦𝘢𝘳 𝘷𝘪𝘴𝘪𝘰𝘯.

📹 Watch the full interview with Dr José Manuel Sandoval, eye surgeon at Hospital Quirónsalud in Málaga, as he shares his firsthand experience using

EyeMax Mono User ExperienceDr José Manuel Sandoval - Hospital Quirónsalud (Málaga).99 Congreso SEO - Sevilla 2023 ...

10/04/2024

🔸 𝘌𝘺𝘦𝘔𝘢𝘹 𝘔𝘰𝘯𝘰 𝘪𝘴 𝘢 𝘷𝘦𝘳𝘺 𝘪𝘯𝘵𝘦𝘳𝘦𝘴𝘵𝘪𝘯𝘨 𝘐𝘖𝘓 𝘧𝘰𝘳 𝘢 𝘴𝘱𝘦𝘤𝘪𝘧𝘪𝘤 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘱𝘳𝘰𝘧𝘪𝘭𝘦 𝘵𝘩𝘢𝘵 𝘤𝘢𝘯 𝘣𝘦𝘯𝘦𝘧𝘪𝘵 𝘮𝘰𝘴𝘵 𝘧𝘳𝘰𝘮 𝘪𝘵, 𝘵𝘩𝘢𝘵 𝘪𝘴 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘧𝘰𝘷𝘦𝘢𝘭 𝘥𝘢𝘮𝘢𝘨𝘦 𝘣𝘶𝘵 𝘪𝘯 𝘸𝘩𝘰𝘮 𝘵𝘩𝘦 𝘳𝘦𝘵𝘪𝘯𝘢𝘭 𝘵𝘪𝘴𝘴𝘶𝘦 𝘪𝘴 𝘩𝘦𝘢𝘭𝘵𝘩𝘺 𝟣𝟢-𝟤𝟢 𝘥𝘦𝘨𝘳𝘦𝘦𝘴 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘵𝘰 𝘵𝘩𝘦 𝘧𝘰𝘷𝘦𝘢

Watch the full interview with Dr Julio Gonzales, who specializes in retinal and vitreous pathologies at the Ramón y Cajal hospital in Madrid, as he shares his firsthand experience using

EyeMax Mono User ExperienceROUND OF INTERVIEWSOn this occasion we have the honor of sharing the testimony of Dr. Julio González, Retina and Vitreous speciali...

27/03/2024

🔸 𝘞𝘪𝘵𝘩 𝘌𝘺𝘦𝘔𝘢𝘹 𝘔𝘰𝘯𝘰, 𝘸𝘦 𝘢𝘤𝘩𝘪𝘦𝘷𝘦 𝘢 𝘵𝘦𝘯-𝘥𝘦𝘨𝘳𝘦𝘦 𝘢𝘳𝘦𝘢 𝘰𝘧 𝘧𝘰𝘤𝘶𝘴. 𝘛𝘩𝘪𝘴 𝘪𝘴 𝘷𝘦𝘳𝘺 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘣𝘦𝘤𝘢𝘶𝘴𝘦 𝘸𝘩𝘦𝘯 𝘵𝘩𝘦 𝘮𝘢𝘤𝘶𝘭𝘢𝘳 𝘥𝘦𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘱𝘳𝘰𝘨𝘳𝘦𝘴𝘴𝘦𝘴 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘤𝘢𝘯𝘯𝘰𝘵 𝘶𝘴𝘦 𝘵𝘩𝘦 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘢𝘳𝘦𝘢 𝘰𝘧 𝘵𝘩𝘦 𝘧𝘰𝘷𝘦𝘢, 𝘸𝘦 𝘤𝘢𝘯 𝘳𝘦𝘭𝘺 𝘰𝘯 𝘵𝘩𝘦 𝘩𝘦𝘢𝘭𝘵𝘩𝘪𝘦𝘳 𝘻𝘰𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘳𝘦𝘵𝘪𝘯𝘢 𝘢𝘯𝘥 𝘢 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘵 𝘗𝘙𝘓 𝘰𝘶𝘵𝘴𝘪𝘥𝘦 𝘵𝘩𝘦 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘢𝘳𝘦𝘢.

📹 Watch the full interview with Dr Patrizia Busatto, Trieste, Italy as she shares her first-hand experience using EyeMax Mono.

EyeMax Mono User ExperienceDr Patrizia Busatto - 41st Congress of ESCRS, Vienna 2023

22/03/2024

🔍 New research suggests a compelling link between sleep deficiency and age-related macular degeneration (AMD). A cross-sectional analysis from NHANES highlights this association, supported by Mendelian randomization findings. These insights underscore the importance of considering sleep health in AMD management.

👇Learn more in this article from HCPLive by Connor Iapoce

https://www.hcplive.com/view/sleep-deficiency-higher-risk-age-related-macular-degeneration

Results from a cross-sectional analysis of NHANES data found a short sleep duration was associated with an increased risk of early AMD.